参考文献/References:
[1] 中华医学会肝病学分会脂肪肝和酒精性肝病学组,中国医师协会脂肪性肝病专家委员会.非酒精性脂肪性肝病防治指南(2018更新版)[J].中华肝脏病杂志,2018,26(3):195-203.
[2] 延 华,张粉利,高艳琼,等.非酒精性脂肪肝与同型半胱氨酸水平及胰岛素抵抗的关系探讨[J].陕西医学杂志,2017,46(10):1451-1452.
[3] 董嘉琪,陈金鹏,龚苏晓,等.山楂的化学成分、药理作用及质量标志物(Q-Marker)预测[J].中草药,2021,52(9):2801-2818.
[4] 张 桥,陈艳琰,乐世俊,等.大黄炮制的历史沿革及对化学成分、传统药理作用影响的研究进展[J].中国中药杂志,2021,46(3):539-551.
[5] 李 莎,寇少杰,薛敬东.薛敬东运用“浊毒理论”治疗非酒精性脂肪肝经验总结[J].陕西中医,2021,42(3):363-365.
[6] 钟 瑾,蒋立文,覃 思,等.槲皮素对化学性肝损伤保护机制的研究及应用进展[J].中国食物与营养,2019,25(9):65-70.
[7] 刘鸣昊,张丽慧,马庆亮,等.槲皮素对非酒精性脂肪性肝炎大鼠的作用及其机制研究[J].中国临床药理学杂志,2019,35(20):2597-2601.
[8] 李 芮,刘 健,靳 楠,等.基于网络药理学探讨当归补血汤治疗再生障碍性贫血作用机制[J].陕西中医,2022,43(3):384-389.
[9] Liu PP,Wu PX,Yang BD,et al.Kaempferol prevents the progression from simple steatosis to non-alcoholic steatohepatitis by inhibiting the NF-κB pathway in oleic acid-induced HepG2 cells and high-fat diet-induced rats[J].Journal of Functional Foods,2021,85:104655.
[10] Liu X,Sun RZ,Li ZZ,et al.Luteolin alleviates non-alcoholic fatty liver disease in rats via restoration of intestinal mucosal barrier damage and microbiota imbalance involving in gut-liver axis[J].Archives of Biochemistry and Biophysics,2021,711:109019.
[11] Huang L,Ding W,Wang MQ,et al.Tanshinone ⅡA ameliorates non-alcoholic fatty liver disease through targeting peroxisome proliferator-activated receptor gamma and toll-like receptor 4[J].Journal of International Medical Research,2019,47(10):5239-5255.
[12] Li XX,Lu XY,Zhang SJ,et al.Sodium tanshinone ⅡA sulfonate ameliorates hepatic steatosis by inhibiting lipogenesis and inflammation[J].Biomedicine & Pharmacotherapy,2019,111(3):68-75.
[13] Sun WL,Liu PP,Wang TQ,et al.Baicalein reduces hepatic fat accumulation by activating AMPK in oleic acid-induced HepG2 cells and high-fat diet-induced non-insulin-resistant mice[J].Food Funct,2020,11(1):711-721.
[14] Cobbina E,Akhlaghi F.Non-alcoholic fatty liver disease(NAFLD)-pathogenesis,classification,and effect on drug metabolizing enzymes and transporters[J].Drug Metabolism Reviews,2017,49(2):197-211.
[15] Pinna F,Bissinger M,Beuke K,et al.A20/TNFAIP3 discriminates tumor necrosis factor(TNF)-induced NF-κB from JNK pathway activation in hepatocytes[J].Frontiers in Physiology,2017,8(7):610.
[16] Gyongyi S,Jan P.Inflammasome activation and function in liver disease[J].Nature Reviews Gastroenterology & Hepatology,2015,12(7):387-400.
[17] 陈 凡,叶俊梅,张玉彬.Akt在心血管疾病中的调控作用[J].药学研究,2018,37(5):291-294,297.
[18] Chen JX,Chen JD,Huang JX,et al.HIF-2α upregulation mediated by hypoxia promotes NAFLD-HCC progression by activating lipid synthesis via the PI3K-AKT-mTOR pathway[J].Aging,2019,11(23):10839-10860.
[19] Xue WJ,Wang JR,Jiang W,et al.Caveolin-1 alleviates lipid accumulation in NAFLD associated with promoting autophagy by inhibiting the Akt/mTOR pathway[J].European Journal of Pharmacology,2020,871:172910.
[20] 杨 洲,叶林森,冯 啸,等.生物信息学分析TP53基因在肝癌中的表达及其对预后的影响[J].中华肝脏外科手术学电子杂志,2022,11(1):87-91.
[21] 刘二冬,侯明慧,王 向,等.携带TP53和ERBB2基因突变的肝细胞癌类器官的培养及药物敏感性鉴定[J].海军军医大学学报,2022,43(6):597-603.
[22] Long JY,Wang AQ,Bai Y,et al.Development and validation of a TP53-associated immune prognostic model for hepatocellular carcinoma[J].EBio Medicine,2019,4(42):363-374.
[23] Bi J,Sun K,Wu H,et al.PPARγ alleviated hepatocyte steatosis through reducing SOCS3 by inhibiting JAK2/STAT3 pathway[J].Biochemical & Biophysical Research Communications,2018,498(4):1037.
[24] 刘丹锋,蔡 魏,邱 剑,等.食源性晚期糖基化终末产物上调TLR4/MyD88/NF-κB信号通路对小鼠非酒精性脂肪肝炎症反应的影响[J].中国老年学杂志,2022,42(24):6035-6039.
[25] 杨 洁,孙 捷,王晓静.晚期糖基化终末产物抑制剂的研究进展[J].中国药物化学杂志,2019,29(5):398-406.
[26] Fernando DH,Forbes JM,Angus PW,et al.Development and progression of non-alcoholic fatty liver disease:The role of advanced glycation end products[J].International Journal of Molecular Sciences,2019,20(20):5037.
[27] 张秋楠,肖 英,苗瑞新,等.非酒精性脂肪性肝病患者肠道菌群变化与胰岛素抵抗指数、肿瘤坏死因子-α和白介素-6的相关性分析[J].临床肝胆病杂志,2015,31(7):1078-1081.
[28] 刘鸣昊,张丽慧,马庆亮,等.槲皮素对非酒精性脂肪性肝炎大鼠的影响[J].中成药,2019,41(8):1820-1825.
[29] 梁国强,葛惠男,章一凡,等.吴门调脂颗粒方对非酒精性脂肪肝大鼠肝组织NF-κBp65/P38MAPK蛋白表达的影响[J].亚太传统医药,2021,17(5):19-23.
相似文献/References:
[1]黄 进,陆雪萍.非酒精性脂肪性肝病从脾论治刍议[J].陕西中医,2021,(2):225.[doi:DOI:10.3969/j.issn.1000-7369.2020.02.022]
HUANG Jin,LU Xueping.Analysis of treatment of nonalcoholic fatty liver disease from spleen[J].,2021,(4):225.[doi:DOI:10.3969/j.issn.1000-7369.2020.02.022]
[2]唐颖慧,叶苗青,何瑾瑜,等.化脂复肝颗粒通过抑制TLR4/NF-κB/NLRP3减轻Kupffer细胞炎症改善非酒精性脂肪性肝病机制研究[J].陕西中医,2022,(10):1359.[doi:DOI:10.3969/j.issn.1000-7369.2022.10.008]
TANG Yinghui,YE Miaoqing,HE Jinyu,et al.Huazhi Fugan granule alleviates Kupffer cell inflammation by inhibiting TLR4/NF-κB/NLRP3 and improves nonalcoholic fatty liver disease[J].,2022,(4):1359.[doi:DOI:10.3969/j.issn.1000-7369.2022.10.008]
[3]赵梦溪,罗 斌,吕建瑞,等.隐丹参酮调节AMPK/Nrf2信号通路治疗小鼠非酒精性脂肪性肝病作用机制[J].陕西中医,2023,(8):1027.[doi:DOI:10.3969/j.issn.1000-7369.2023.08.007]
ZHAO Mengxi,LUO Bin,LYU Jianrui,et al.Mechanism of cryptotanshinone regulates AMPK/Nrf2 signaling pathway to treat nonalcoholic fatty liver disease in mouse[J].,2023,(4):1027.[doi:DOI:10.3969/j.issn.1000-7369.2023.08.007]
[4]杨 帆,李 娟,何 昉,等.利胆退黄汤治疗非酒精性脂肪性肝病疗效及对患者肝功能、糖脂代谢和血清脂肪因子的影响[J].陕西中医,2023,(10):1404.[doi:DOI:10.3969/j.issn.1000-7369.2023.10.015]
YANG Fan,LI Juan,HE Fang,et al.Lidan Tuihuang decoction on liver function,glycolipid metabolism,and serum adipose factors in the treatment of non alcoholic fatty liver disease[J].,2023,(4):1404.[doi:DOI:10.3969/j.issn.1000-7369.2023.10.015]
[5]李秀秀,张玉佩,许春玲,等.基于胆汁酸-肠道菌群对话机制探讨非酒精性脂肪性肝病肝郁脾虚病机特点[J].陕西中医,2024,(6):798.[doi:DOI:10.3969/j.issn.1000-7369.2024.06.016]
LI Xiuxiu,ZHANG Yupei,XU Chunling,et al.Exploration of the pathogenic characteristics of non-alcoholic fatty liver disease with liver depression and spleen deficiency based on the bile acid-gut microbiota dialogue mechanism[J].,2024,(4):798.[doi:DOI:10.3969/j.issn.1000-7369.2024.06.016]
[6]罗 艺,周晓玲,刘 琳,等.非酒精性脂肪性肝病中医治疗研究进展[J].陕西中医,2024,(6):859.[doi:DOI:10.3969/j.issn.1000-7369.2024.06.030]
LUO Yi,ZHOU Xiaoling,LIU Lin,et al.Research progress on traditional Chinese medicine treatment of nonalcoholic fatty liver disease[J].,2024,(4):859.[doi:DOI:10.3969/j.issn.1000-7369.2024.06.030]